Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Paige Erdeljac"'
Autor:
Nicole Williams, Anne M. Noonan, Bhuvaneswari Ramaswamy, Erin E. Holley, Susan Fugett, Paige Erdeljac, Cari Utendorf, Julie A. Stephens, Stephanie Yager, Nikki Ford, Caitln Ubbing, Jeanie Overcash, Elizabeth Kress, Erin Frey
Publikováno v:
Cancer Research. 80:P4-16
Introduction: Adults age ≥65y constitute the majority of patients (pts) diagnosed with cancer. There is a gap in knowledge about the safest and most effect cancer treatments for older pts. At The Ohio State University, we have a longitudinal multid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79ba6ffd029cc650ff2bdfa765e53192
https://doi.org/10.1158/1538-7445.sabcs19-p4-16-01
https://doi.org/10.1158/1538-7445.sabcs19-p4-16-01
Publikováno v:
Drug, Healthcare and Patient Safety
The care of older patients with cancer is becoming increasingly complex. Common challenges for this population include management of comorbidities, safe transitions of care, and appropriate medication use. In particular, polypharmacy—generally defi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32a69a0652180b1d75ae7be5e16c881
https://pubmed.ncbi.nlm.nih.gov/33953612
https://pubmed.ncbi.nlm.nih.gov/33953612
Autor:
H. Paige Erdeljac, Anne M. Noonan, Susan Fugett, Brittany Knauss, Janine Overcash, Sandra Abels, Elizabeth Kress, Cari Utendorf
Publikováno v:
Oncology Issues. 33:54-61
Cancer is a common comorbidity often associated with aging. Older patients can have specific needs such as caregiver concerns, transportation challenges, limited social support, and other problems ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::057291098945bc8b241b0ca7d53df79b
https://doi.org/10.1080/10463356.2018.1456106
https://doi.org/10.1080/10463356.2018.1456106
Autor:
Tracy Wiczer, Megan K Phelps, H. Paige Erdeljac, Tzu-Fei Wang, Gary Philips, Kelsey R Van Deusen, Kyle Porter
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:793-800
Introduction Low-molecular-weight heparins are the standard treatment for cancer-associated thrombosis. Recently, direct oral anticoagulants are a new option for thrombosis treatment; however, data supporting the use of direct oral anticoagulants for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48ac426c32ddcae33c4f91cb88d95461
https://doi.org/10.1177/1078155218757856
https://doi.org/10.1177/1078155218757856
Autor:
Desiree Jones, H. Paige Erdeljac, ReNea Owens, Katherine Mitchell, Anna Maria Bittoni, Elyse Redder, Amy Compston, Sarah A Wall, Shelley Foster, Heather Johns, Stephanie Yager, Amy Custer, Kimberly Holt, Ying Huang, Ashley E. Rosko, Madison Grogan, Wendy Ricketts
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S116
Introduction The use of alternative donor sources has led to increased access to allogeneic stem cell transplantation (allo-SCT) for older adults (OA) who are less likely to have healthy siblings able to serve as donors. Reduced intensity conditionin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1499eef521d6562b826729da41ef8e8f
https://doi.org/10.1016/j.bbmt.2019.12.627
https://doi.org/10.1016/j.bbmt.2019.12.627
Autor:
H. Paige Erdeljac, Aaron Dush
Publikováno v:
Journal of Pharmacy Practice. 33:390-391
Management of patients with antiphospholipid syndrome on warfarin therapy can be challenging. The international normalized ratio (INR) of patients with antiphospholipid syndrome can be falsely elevated. This elevation is thought to be reflective of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284e06d505ee0b37613d4c079062d8c2
https://doi.org/10.1177/0897190019838192
https://doi.org/10.1177/0897190019838192
Autor:
Kelsey R Van Deusen, Tzu-Fei Wang, Gary Phillips, Kyle Porter, Megan K Phelps, Tracy Wiczer, H. Paige Erdeljac
Publikováno v:
Blood. 128:5013-5013
Background Venous thromboembolism (VTE) is the second leading cause of mortality in cancer patients. National guidelines recommend treatment with a low-molecular-weight heparin (LMWH) for at least 6 months following a cancer-associated thrombosis (CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75db0ff522876d70e54a369ccbda167c
https://doi.org/10.1182/blood.v128.22.5013.5013
https://doi.org/10.1182/blood.v128.22.5013.5013